A randomized, blinded, placebo and positive-controlled 4-way crossover study to study the effect of multiple doses of apixaban on the QTc interval in healthy subjects.
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Apixaban (Primary) ; Moxifloxacin
- Indications Thromboembolism
- Focus Therapeutic Use
- 23 Nov 2015 New trial record